

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock code: 1093)

ANNOUNCEMENT

KEY FINANCIAL INFORMATION OF A SUBSIDIARY FOR THE YEAR ENDED 31 DECEMBER 2023

This announcement is made by CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company wishes to update its shareholders and potential investors that CSPC Innovation Pharmaceutical Co., Ltd. (“**CSPC Innovation**”), an indirect non-wholly owned subsidiary of the Company of which its shares are listed on the ChiNext of Shenzhen Stock Exchange (Stock Code: 300765.SZ), has on 24 January 2024 published an announcement (the “**CSPC Innovation Announcement**”) on the webpage of the Shenzhen Stock Exchange’s website at <http://www.szse.cn/disclosure/listed/notice/index.html> in relation to its proposed acquisition of 100% equity interest in CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (“**CSPC Baike**”), an indirect wholly-owned subsidiary of the Company, from certain indirect wholly-owned subsidiaries of the Company. The consideration (including the number of new shares of CSPC Innovation to be issued and the amount of cash consideration) of such proposed transaction has not been determined.

As informed by CSPC Innovation, for the purposes of compliance with relevant requirements of the Shenzhen Stock Exchange, it has disclosed in the CSPC Innovation Announcement, among other things, the unaudited financial information of CSPC Baike for the financial year ended 31 December 2023 (the “**CSPC Baike’s Financial Information**”) as follows:

	<i>For the financial year ended 31 December 2023 RMB'000</i>
Total assets	4,718,695.4
Total liabilities	634,819.8
Equity attributable to the company owners	4,083,875.6
Revenue	2,663,363.6
Net profit	859,018.7

The CSPC Baike’s Financial Information was prepared based on the unaudited management accounts of CSPC Baike for the financial year ended 31 December 2023 in accordance with the China Accounting Standards for Business Enterprises, which have not been audited or reviewed by the auditor or the audit committee of the Company. Shareholders and potential investors of the Company are reminded that the CSPC Baike’s Financial Information above only relates to the financial information of one of the subsidiaries of the Company, and does not give a complete view of the results of operation and financial positions of the Group in general. Shareholders and potential investors of the Company should exercise caution when considering the above CSPC Baike’s Financial Information and when dealing in the securities of the Company.

CSPC Baike is an innovative biopharmaceutical company established in the People’s Republic of China committed to the research, development and commercialization of innovative biopharmaceuticals such as long-acting protein drugs, with Jinyouli (津優力®) (PEG-rhGCSF injection) as its principal product.

Further announcement(s) will be made by the Company in respect of the proposed transaction concerning CSPC Baike as and when appropriate in accordance with the Listing Rules.

WARNING: Shareholders and/or potential investors of the Company are reminded that the proposed transaction is subject to, among other things, the entering into of a formal sale and purchase agreement, which terms are still under negotiation. Accordingly, the proposed transaction may or may not be materialised.

Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company. Persons who are in doubt as to the action they should take should consult their stock brokers, bank managers, solicitors or other professional advisers.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 24 January 2024

As at the date of this announcement, the board of directors of the Company comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi, Mr. CHAK Kin Man and Dr. JIANG Hao as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.